BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 24620626)

  • 1. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
    Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
    Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania.
    Moraru IG; Moraru AG; Andrei M; Iordache T; Drug V; Diculescu M; Portincasa P; Dumitrascu DL
    Rom J Intern Med; 2014; 52(3):143-50. PubMed ID: 25509557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
    Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.
    Weinstock LB; Geng B; Brandes SB
    Can J Urol; 2011 Aug; 18(4):5826-30. PubMed ID: 21854715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
    Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
    Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.
    Scarpellini E; Giorgio V; Gabrielli M; Filoni S; Vitale G; Tortora A; Ojetti V; Gigante G; Fundarò C; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1314-20. PubMed ID: 23740443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin.
    Cuoco L; Salvagnini M
    Minerva Gastroenterol Dietol; 2006 Mar; 52(1):89-95. PubMed ID: 16554709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy.
    Lombardo L; Foti M; Ruggia O; Chiecchio A
    Clin Gastroenterol Hepatol; 2010 Jun; 8(6):504-8. PubMed ID: 20060064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microscopic colitis and small intestinal bacterial overgrowth--diagnosis behind the irritable bowel syndrome?
    Stoicescu A; Andrei M; Becheanu G; Stoicescu M; Nicolaie T; Diculescu M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):766-72. PubMed ID: 23272525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
    Majewski M; McCallum RW
    Adv Med Sci; 2007; 52():139-42. PubMed ID: 18217406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?
    Aziz I; Törnblom H; Simrén M
    Curr Opin Gastroenterol; 2017 May; 33(3):196-202. PubMed ID: 28257307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.
    Peralta S; Cottone C; Doveri T; Almasio PL; Craxi A
    World J Gastroenterol; 2009 Jun; 15(21):2628-31. PubMed ID: 19496193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
    Zhuang X; Tian Z; Luo M; Xiong L
    BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial.
    Ghoshal UC; Srivastava D; Misra A; Ghoshal U
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):281-9. PubMed ID: 26731696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture.
    Ghoshal UC; Srivastava D; Ghoshal U; Misra A
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):753-60. PubMed ID: 24849768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution.
    Parodi A; Dulbecco P; Savarino E; Giannini EG; Bodini G; Corbo M; Isola L; De Conca S; Marabotto E; Savarino V
    J Clin Gastroenterol; 2009; 43(10):962-6. PubMed ID: 19525858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.
    Collins BS; Lin HC
    J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):382-6. PubMed ID: 21240023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifaximin treatment for symptoms of irritable bowel syndrome.
    Fumi AL; Trexler K
    Ann Pharmacother; 2008 Mar; 42(3):408-12. PubMed ID: 18303148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome.
    Posserud I; Stotzer PO; Björnsson ES; Abrahamsson H; Simrén M
    Gut; 2007 Jun; 56(6):802-8. PubMed ID: 17148502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.
    Ghoshal UC; Shukla R; Ghoshal U
    Gut Liver; 2017 Mar; 11(2):196-208. PubMed ID: 28274108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.